Molecular and immunohistochemical testing of bone tumours: review and update
暂无分享,去创建一个
Y. Hung | G. Nielsen | S. K. Kovacs | Atikankul Manassaporn | G. P. Nielsen | S Krisztian Kovacs | Yin P Hung
[1] A. Flanagan,et al. Brown Tumors Belong to the Spectrum of KRAS-driven Neoplasms , 2022, The American journal of surgical pathology.
[2] A. Franchi,et al. Chondroblastoma‐like osteosarcoma: a clinicopathological and molecular study of a rare osteosarcoma variant , 2022, Histopathology.
[3] M. Larsen,et al. Integrated proteomics, phosphoproteomics and metabolomics analyses reveal similarities amongst giant cell granulomas of the jaws with different genetic mutations. , 2022, Journal of Oral Pathology & Medicine.
[4] Jonathan C. Baker,et al. Xanthogranulomatous epithelial tumors and keratin-positive giant cell-rich soft tissue tumors: two aspects of a single entity with frequent HMGA2-NCOR2 fusions , 2022, Modern Pathology.
[5] Jianyun Zhang,et al. GNAS mutation analysis assists in differentiating chronic diffuse sclerosing osteomyelitis from fibrous dysplasia in the jaw , 2022, Modern Pathology.
[6] C. Kunder,et al. GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics , 2022, The American journal of surgical pathology.
[7] T. Shibata,et al. Co-expression of ERG and CD31 in a subset of CIC-rearranged sarcoma: a potential diagnostic pitfall , 2022, Modern Pathology.
[8] D. Baumhoer,et al. Methylation and copy number profiling: emerging tools to differentiate osteoblastoma from malignant mimics? , 2022, Modern Pathology.
[9] Christopher Davies,et al. A genetic model for central chondrosarcoma evolution correlates with patient outcome , 2021, Genome Medicine.
[10] L. Gorunova,et al. Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (HMGA2) and Nuclear Receptor Co-repressor 2 (NCOR2) in Osteoclastic Giant Cell-rich Tumors of Bone , 2022, Cancer Genomics & Proteomics.
[11] Y. Oda,et al. Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation , 2021, Modern Pathology.
[12] E. Wardelmann,et al. Recurrent CTNNB1 mutations in craniofacial osteomas , 2021, Modern Pathology.
[13] Liang Jiang,et al. CIC-NUTM1 Sarcomas Affecting the Spine: A Subset of CIC-Rearranged Sarcomas Commonly Present in the Axial Skeleton. , 2021, Archives of pathology & laboratory medicine.
[14] M. Hameed,et al. Recurrent loss of chromosome 22 and SMARCB1 deletion in extra‐axial chordoma: A clinicopathological and molecular analysis , 2021, Genes, chromosomes & cancer.
[15] C. Antonescu,et al. A unique epithelioid vascular neoplasm of bone characterized by EWSR1/FUS‐NFATC1/2 fusions , 2021, Genes, chromosomes & cancer.
[16] Edward J. Fox,et al. Novel fusion sarcomas including targetable NTRK and ALK. , 2021, Annals of diagnostic pathology.
[17] E. Montgomery,et al. Novel fusion genes in spindle cell rhabdomyosarcoma: The spectrum broadens , 2021, Genes, chromosomes & cancer.
[18] A. Cleton-Jansen,et al. NTRK fusions are extremely rare in bone tumours , 2021, Histopathology.
[19] M. Rivera,et al. Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue Tumors , 2021, The American journal of surgical pathology.
[20] B. Mavčič,et al. The role of molecular diagnostics in aneurysmal and simple bone cysts – a prospective analysis of 19 lesions , 2021, Virchows Archiv.
[21] Daja Šekoranja,et al. Fibroma of tendon sheath is defined by a USP6 gene fusion—morphologic and molecular reappraisal of the entity , 2021, Modern Pathology.
[22] A. Cleton-Jansen,et al. Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors , 2021, The American journal of surgical pathology.
[23] R. Seethala,et al. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck , 2021, The American journal of surgical pathology.
[24] A. Luebke,et al. H3F3A‐mutated giant cell tumour of bone without giant cells—clinical presentation, radiology and histology of three cases , 2021, Histopathology.
[25] A. Folpe,et al. Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors , 2021, Modern Pathology.
[26] Yuehua Wu,et al. Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis , 2021, Modern Pathology.
[27] D. Baumhoer,et al. FOS Rearrangement and Expression in Cementoblastoma , 2021, The American journal of surgical pathology.
[28] A. Vargas,et al. NKX3.1 immunohistochemistry is highly specific for the diagnosis of mesenchymal chondrosarcomas: experience in the Australian population. , 2021, Pathology.
[29] Y. Yatabe,et al. Confirmation of NKX3-1 Expression in EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma Using Monoclonal Antibody Immunohistochemistry, RT-PCR, and RNA In Situ Hybridization. , 2021, The American journal of surgical pathology.
[30] Narasimhan P. Agaram,et al. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases , 2020, Histopathology.
[31] A. Iafrate,et al. Identification of EWSR1–NFATC2 fusion in simple bone cysts , 2020, Histopathology.
[32] A. Horvai,et al. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma. , 2020, The American journal of surgical pathology.
[33] A. Horvai,et al. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma. , 2020, Archives of pathology & laboratory medicine.
[34] Ž. Snoj,et al. FUS-NFATC2 or EWSR1-NFATC2 Fusions Are Present in a Large Proportion of Simple Bone Cysts , 2020, The American journal of surgical pathology.
[35] M. Hameed,et al. Poorly differentiated chordoma with whole‐genome doubling evolving from a SMARCB1‐deficient conventional chordoma: A case report , 2020, Genes, chromosomes & cancer.
[36] C. Fletcher,et al. NKX3.1 immunoreactivity is not identified in mesenchymal chondrosarcoma: a 25‐case cohort study , 2020, Histopathology.
[37] C. Fletcher,et al. Clinicopathologic characterization of malignant chondroblastoma: a neoplasm with locally aggressive behavior and metastatic potential that closely mimics chondroblastoma-like osteosarcoma , 2020, Modern Pathology.
[38] D. Spierings,et al. Loss of NF2 defines a genetic subgroup of non‐FOS‐rearranged osteoblastoma , 2020, The journal of pathology. Clinical research.
[39] David C. Jones,et al. Drivers underpinning the malignant transformation of giant cell tumour of bone , 2020, medRxiv.
[40] A. Franchi,et al. Synovial chondrosarcoma: a single‐institution experience with molecular investigations and review of the literature , 2020, Histopathology.
[41] F. Tirode,et al. NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker , 2020, Modern Pathology.
[42] Narasimhan P. Agaram,et al. Myositis ossificans-like soft tissue aneurysmal bone cyst: a clinical, radiological, and pathological study of seven cases with COL1A1-USP6 fusion and a novel ANGPTL2-USP6 fusion , 2020, Modern Pathology.
[43] O. Witt,et al. NTRK fusions in osteosarcoma are rare and non‐functional events , 2020, The journal of pathology. Clinical research.
[44] Ž. Snoj,et al. Novel ASAP1‐USP6, FAT1‐USP6, SAR1A‐USP6, and TNC‐USP6 fusions in primary aneurysmal bone cyst , 2020, Genes, chromosomes & cancer.
[45] C. Antonescu,et al. NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma , 2020, The American journal of surgical pathology.
[46] Narasimhan P. Agaram,et al. A molecular study of synovial chondromatosis , 2020, Genes, chromosomes & cancer.
[47] P. Hoffstetter,et al. ZFP36–FOSB fusion in a haemorrhagic epithelioid and spindle cell haemangioma of bone: is there a family of FOSB‐rearranged vascular neoplasms of the bone? , 2020, Histopathology.
[48] M. Harris,et al. Recurrent and novel USP6 fusions in cranial fasciitis identified by targeted RNA sequencing , 2019, Modern Pathology.
[49] J. Bovée,et al. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma , 2019, Virchows Archiv.
[50] Narasimhan P. Agaram,et al. Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma , 2019, Clinical Cancer Research.
[51] Narasimhan P. Agaram,et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets , 2019, Modern Pathology.
[52] C. Antonescu,et al. Pericytoma With t(7;12) and ACTB-GLI1 Fusion , 2019, The American journal of surgical pathology.
[53] J. Bovée,et al. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis , 2019, Histopathology.
[54] S. Salas,et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation , 2019, Modern Pathology.
[55] M. Ladanyi,et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls , 2019, Modern Pathology.
[56] C. Antonescu,et al. EWSR1/FUS - NFATc2 rearranged round cell sarcoma: Clinicopathological series of four cases and literature review. , 2019, Human pathology.
[57] T. Shibata,et al. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone , 2019, Modern Pathology.
[58] D. Huen,et al. Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors , 2019, The American journal of surgical pathology.
[59] A. Flanagan,et al. Synovial chondromatosis and soft tissue chondroma: extra-osseous cartilaginous tumours defined by FN1 gene rearrangement , 2019, Modern Pathology.
[60] A. Iafrate,et al. Molecular characteristics of poorly differentiated chordoma , 2019, Genes, chromosomes & cancer.
[61] P. Szépe,et al. Fibro-osseous pseudotumor of digits and myositis ossificans show consistent COL1A1-USP6 rearrangement: a clinicopathological and genetic study of 27 cases. , 2019, Human pathology.
[62] Narasimhan P. Agaram,et al. Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype , 2019, The American journal of surgical pathology.
[63] E. Wardelmann,et al. Activating mutations in the MAP‐kinase pathway define non‐ossifying fibroma of bone , 2019, The Journal of pathology.
[64] H. Ichikawa,et al. Novel NTRK3 Fusions in Fibrosarcomas of Adults , 2019, The American journal of surgical pathology.
[65] A. Cleton-Jansen,et al. Molecular Pathology of Bone Tumors. , 2019, The Journal of molecular diagnostics : JMD.
[66] J. Fantasia,et al. USP6 Gene Rearrangement by FISH Analysis in Cranial Fasciitis: A Report of Three Cases , 2019, Head and Neck Pathology.
[67] A. Flanagan,et al. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing , 2019, Genes, chromosomes & cancer.
[68] C. Antonescu,et al. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone , 2018, The Journal of pathology.
[69] A. Flanagan,et al. FOS Expression in Osteoid Osteoma and Osteoblastoma A Valuable Ancillary Diagnostic Tool , 2019 .
[70] D. Sinnett,et al. TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw , 2018, Nature Communications.
[71] N. Hiraoka,et al. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features , 2018, Modern Pathology.
[72] Jessica L. Davis,et al. Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma , 2018, Modern Pathology.
[73] Hong Yang,et al. Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis , 2018, The American journal of surgical pathology.
[74] H. Ichikawa,et al. PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours , 2018, Histopathology.
[75] J. Fletcher,et al. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy , 2018, Cancer cytopathology.
[76] C. Fletcher,et al. Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.
[77] A. Folpe,et al. Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall. , 2018, Human pathology.
[78] Asha A. Nair,et al. Spindle cell rhabdomyosarcoma of bone with FUS–TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype , 2018, Histopathology.
[79] Matthew D. Young,et al. Recurrent rearrangements of FOS and FOSB define osteoblastoma , 2018, Nature Communications.
[80] Peter J. Park,et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing , 2018, bioRxiv.
[81] O. Delattre,et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas , 2018, The Journal of pathology.
[82] David T. W. Jones,et al. Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information , 2018, Modern Pathology.
[83] G. Nielsen,et al. Clinicopathologic characteristics of poorly differentiated chordoma , 2018, Modern Pathology.
[84] Y. Oda,et al. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. , 2017, Human pathology.
[85] Y. Ishikawa,et al. Osteosarcoma arising in fibrous dysplasia, confirmed by mutational analysis of GNAS gene. , 2017, Pathology, research and practice.
[86] C. Antonescu,et al. BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas , 2017, The American journal of surgical pathology.
[87] A. Iafrate,et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. , 2017, JCO precision oncology.
[88] Matthew D. Young,et al. The driver landscape of sporadic chordoma , 2017, Nature Communications.
[89] M. Rijn,et al. EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma , 2017, Modern Pathology.
[90] Wei-Lien Wang,et al. USP6 activation in nodular fasciitis by promoter-swapping gene fusions , 2017, Modern Pathology.
[91] T. Barth,et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant , 2017, Histopathology.
[92] C. Antonescu,et al. Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases , 2017, The American journal of surgical pathology.
[93] Daniel Baumhoer,et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma , 2017, Nature Communications.
[94] C. Antonescu,et al. ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements , 2017, Genes, chromosomes & cancer.
[95] A. Flanagan,et al. H3F3A (Histone 3.3) G34W Immunohistochemistry , 2017, The American journal of surgical pathology.
[96] David T. W. Jones,et al. Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases , 2017, Clinical Sarcoma Research.
[97] C. Fletcher,et al. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma , 2017, The American journal of surgical pathology.
[98] R. Sompallae,et al. Anchored multiplex PCR for targeted next‐generation sequencing reveals recurrent and novel USP6 fusions and upregulation of USP6 expression in aneurysmal bone cyst , 2017, Genes, chromosomes & cancer.
[99] A. Folpe,et al. Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors , 2016, Modern Pathology.
[100] Narasimhan P. Agaram,et al. Secondary EWSR1 gene abnormalities in SMARCB1‐deficient tumors with 22q11‐12 regional deletions: Potential pitfalls in interpreting EWSR1 FISH results , 2016, Genes, chromosomes & cancer.
[101] Gaëlle Pérot,et al. ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas: a study of 127 cases including mimicking lesions , 2016, Modern Pathology.
[102] C. Fletcher,et al. Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics , 2016, Modern Pathology.
[103] Narasimhan P. Agaram,et al. BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities , 2016, The American journal of surgical pathology.
[104] M. Ladanyi,et al. Genomic aberrations frequently alter chromatin regulatory genes in chordoma , 2016, Genes, chromosomes & cancer.
[105] A. Flanagan,et al. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma , 2016, Histopathology.
[106] Narasimhan P. Agaram,et al. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations , 2016, The American journal of surgical pathology.
[107] P. Brousset,et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[108] A. Folpe,et al. Primary Pseudomyogenic Hemangioendothelioma of Bone , 2016, The American journal of surgical pathology.
[109] C. Fletcher,et al. Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma , 2016, Modern Pathology.
[110] Jacques P. Brown,et al. ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor , 2016, American journal of human genetics.
[111] C. Fletcher,et al. Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics , 2016, The American journal of surgical pathology.
[112] Florian Engert,et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency , 2015, Nature Communications.
[113] M. Hisaoka,et al. CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma , 2015, Histopathology.
[114] A. Cleton-Jansen,et al. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma , 2015, The American journal of surgical pathology.
[115] Narasimhan P. Agaram,et al. Frequent FOS Gene Rearrangements in Epithelioid Hemangioma: A Molecular Study of 58 Cases With Morphologic Reappraisal , 2015, The American journal of surgical pathology.
[116] P. Hogendoorn,et al. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype , 2015, Histopathology.
[117] T. Forshew,et al. GNAS mutations are not detected in parosteal and low-grade central osteosarcomas , 2015, Modern Pathology.
[118] A. Folpe,et al. Identification of a novel FN1–FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour , 2015, The Journal of pathology.
[119] C. Antonescu,et al. Array CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone , 2015, Genes, chromosomes & cancer.
[120] Donna M. Muzny,et al. BCOR-CCNB3 Fusions Are Frequent in Undifferentiated Sarcomas of Male Children , 2014, Modern Pathology.
[121] Narasimhan P. Agaram,et al. ZFP36‐FOSB fusion defines a subset of epithelioid hemangioma with atypical features , 2014, Genes, chromosomes & cancer.
[122] H. Douis,et al. BCOR-CCNB3 (Ewing-like) Sarcoma: A Clinicopathologic Analysis of 10 Cases, In Comparison With Conventional Ewing Sarcoma , 2014, The American journal of surgical pathology.
[123] S. Miyano,et al. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma , 2014, Genome research.
[124] Jianxin Shi,et al. Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma , 2014, Human Genetics.
[125] Narasimhan P. Agaram,et al. USP6 gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gnathic location. , 2014, Human pathology.
[126] P. D. Dal Cin,et al. Nuclear protein in testis midline carcinoma misdiagnosed as adamantinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] Li Ding,et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.
[128] D. Jong,et al. GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma , 2014, Nature Genetics.
[129] M. Stratton,et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma , 2014, Nature Genetics.
[130] A. Cleton-Jansen,et al. Recurrent Chromosome 22 Deletions in Osteoblastoma Affect Inhibitors of the Wnt/Beta-Catenin Signaling Pathway , 2013, PloS one.
[131] M. Stratton,et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.
[132] J. Hornick,et al. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours , 2013, Histopathology.
[133] S. Aubert,et al. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions , 2013, Modern Pathology.
[134] G. Nielsen,et al. Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations , 2013, The American journal of surgical pathology.
[135] A. B. Hassan,et al. Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy , 2013, Clinical Cancer Research.
[136] A. Folpe,et al. A Benign Vascular Tumor With a New Fusion Gene: EWSR1-NFATC1 in Hemangioma of the Bone , 2013, The American journal of surgical pathology.
[137] Yan Chen,et al. GNAS mutational analysis in differentiating fibrous dysplasia and ossifying fibroma of the jaw , 2013, Modern Pathology.
[138] R. Lothe,et al. Whole-Transcriptome Sequencing Identifies Novel IRF2BP2-CDX1 Fusion Gene Brought about by Translocation t(1;5)(q42;q32) in Mesenchymal Chondrosarcoma , 2012, PloS one.
[139] P. Talmud,et al. A common single-nucleotide variant in T is strongly associated with chordoma , 2012, Nature Genetics.
[140] T. Seemayer,et al. Pericytoma with t(7;12) and ACTB-GLI1 fusion arising in bone. , 2012, Human pathology.
[141] H. Tsuda,et al. NKX2.2 is a Useful Immunohistochemical Marker for Ewing Sarcoma , 2012, The American journal of surgical pathology.
[142] O. Delattre,et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion , 2012, Nature Genetics.
[143] T. Shibata,et al. MDM2 and CDK4 Immunohistochemical Coexpression in High-grade Osteosarcoma: Correlation With a Dedifferentiated Subtype , 2012, The American journal of surgical pathology.
[144] N. Socci,et al. Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data , 2012, Genes, chromosomes & cancer.
[145] A. Flanagan,et al. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes , 2012, Histopathology.
[146] A. Futreal,et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2 , 2011, Nature Genetics.
[147] R. Sciot,et al. Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome , 2011, Nature Genetics.
[148] M. Chou,et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion , 2011, Laboratory Investigation.
[149] A. Grigoriadis,et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.
[150] Julie M. Batten,et al. Recurrent Chromosomal Copy Number Alterations in Sporadic Chordomas , 2011, PloS one.
[151] L. Guillou,et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone , 2011, Modern Pathology.
[152] J. Seidman,et al. Loss-of-Function Mutations in PTPN11 Cause Metachondromatosis, but Not Ollier Disease or Maffucci Syndrome , 2011, PLoS genetics.
[153] P. Casali,et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. , 2010, Neuro-oncology.
[154] T. Shibata,et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics , 2010, Modern Pathology.
[155] J. Wunder,et al. Characterization of the 12q15 MDM2 and 12q13‐14 CDK4 amplicons and clinical correlations in osteosarcoma , 2010, Genes, chromosomes & cancer.
[156] S. Mukherji,et al. Sino-orbital osteoma: a clinicopathologic study of 45 surgically treated cases with emphasis on tumors with osteoblastoma-like features. , 2009, Archives of pathology & laboratory medicine.
[157] A. Goldstein,et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma , 2009, Nature Genetics.
[158] S. Knuutila,et al. Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors , 2009, Clinical Cancer Research.
[159] H. Tanke,et al. The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to Oncology , 2009, Clinical Cancer Research.
[160] J. O'Connell,et al. Epithelioid Hemangioma of Bone Revisited: A Study of 50 Cases , 2009, The American journal of surgical pathology.
[161] A. Flanagan,et al. A sensitive mutation‐specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone , 2007, Histopathology.
[162] S. Henderson,et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas , 2006, The Journal of pathology.
[163] G. Siegal,et al. Osteosarcoma: anatomic and histologic variants. , 2006, American journal of clinical pathology.
[164] J. Fletcher,et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. , 2004, The American journal of pathology.
[165] A. Stemmer-Rachamimov,et al. Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2 , 2004, Genes, chromosomes & cancer.
[166] J. Fletcher,et al. USP6 (Tre2) Fusion Oncogenes in Aneurysmal Bone Cyst , 2004, Cancer Research.
[167] J. O'Connell,et al. Chondroblastoma-Like Chondroma of Soft Tissue: An Underrecognized Variant and Its Differential Diagnosis , 2001, The American journal of surgical pathology.
[168] Dale E. Jarka,et al. Osteochondromyxoma of Bone: A Congenital Tumor Associated With Lentigines and Other Unusual Disorders , 2001, The American journal of surgical pathology.
[169] C. Stratakis,et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex , 2000, Nature Genetics.
[170] M. Ushijima,et al. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. , 2000, Virchows Archiv : an international journal of pathology.
[171] A. Cleton-Jansen,et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis , 1999, The Journal of pathology.
[172] G. Nielsen,et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. , 1999, The American journal of surgical pathology.
[173] A. Cleton-Jansen,et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. , 1999, American journal of human genetics.
[174] A. Rosenberg,et al. Hemorrhagic epithelioid and spindle cell hemangioma , 1999, Cancer.
[175] K. Eppert,et al. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas , 1999, Oncogene.
[176] C. Inwards,et al. Chondromyxoid fibroma of bone: a clinicopathologic review of 278 cases. , 1998, Human pathology.
[177] S. Knuutila,et al. Comparative genomic hybridization of low-grade central osteosarcoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[178] M. Lovett,et al. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes , 1996, Nature Genetics.
[179] M. Wagner,et al. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1) , 1995, Nature Genetics.
[180] T. Ishida,et al. Massive chondroid differentiation in fibrous dysplasia of bone (fibrocartilaginous dysplasia) , 1993, The American journal of surgical pathology.
[181] J. O'Connell,et al. Epithelioid Hemangioma of Bone: A Tumor Often Mistaken for Low-Grade Angiosarcoma or Malignant Hemangioendothelioma , 1993, The American journal of surgical pathology.
[182] G. Thomas,et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.
[183] M. Merino,et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. , 1991, The New England journal of medicine.
[184] A. Cabrera,et al. EWING'S SARCOMA. , 1964, Surgery, gynecology & obstetrics.